1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305.
Article
2. Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011; 26:379–385.
Article
3. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020; 43:Suppl 1. S111–S134.
4. Palanca A, Castelblanco E, Perpinan H, Betriu A, Soldevila B, Valdivielso JM, Bermudez M, Duran X, Fernandez E, Puig-Domingo M, Groop PH, Alonso N, Mauricio D. Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes. Atherosclerosis. 2018; 276:50–57.
Article
5. Betriu A, Martinez-Alonso M, Arcidiacono MV, Cannata-Andia J, Pascual J, Valdivielso JM, Fernandez E. Investigators from the NEFRONA Study. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrol Dial Transplant. 2014; 29:1415–1422.
Article
6. Seo DH, Kim SH, Song JH, Hong S, Suh YJ, Ahn SH, Woo JT, Baik SH, Park Y, Lee KW, Kim YS, Nam M. KNDP Study Group. Presence of carotid plaque is associated with rapid renal function decline in patients with type 2 diabetes mellitus and normal renal function. Diabetes Metab J. 2019; 43:840–853.
Article
7. Kaneko R, Sawada S, Tokita A, Honkura R, Tamura N, Kodama S, Izumi T, Takahashi K, Uno K, Imai J, Yamada T, Miyachi Y, Hasegawa H, Kanai H, Ishigaki Y, Katagiri H. Serum cystatin C level is associated with carotid arterial wall elasticity in subjects with type 2 diabetes mellitus: a potential marker of early-stage atherosclerosis. Diabetes Res Clin Pract. 2018; 139:43–51.
Article
8. Takenouchi A, Tsuboi A, Kurata M, Fukuo K, Kazumi T. Carotid intima-media thickness and visit-to-visit HbA1c variability predict progression of chronic kidney disease in type 2 diabetic patients with preserved kidney function. J Diabetes Res. 2016; 2016:3295747.
Article
9. Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol. 2017; 312:F716–F731.
Article
10. Pindjakova J, Hanley SA, Duffy MM, Sutton CE, Weidhofer GA, Miller MN, Nath KA, Mills KH, Ceredig R, Griffin MD. Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction. Kidney Int. 2012; 81:379–390.
Article
11. Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010; 78:351–362.
Article